What Tesamorelin Is & How It Works
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog designed to stimulate the pituitary gland to release endogenous growth hormone (GH). By increasing GH secretion, Tesamorelin indirectly promotes the production of insulin-like growth factor 1 (IGF-1), which supports cellular growth, tissue repair, and metabolic regulation. Its mechanism differs from direct GH injections because it encourages the body’s natural hormone rhythms, reducing the risk of GH-related side effects seen with exogenous administration (PubMed).

Clinical Evidence & Outcomes
Tesamorelin has been studied extensively in both metabolic and tissue-regeneration contexts. In clinical trials involving HIV-associated lipodystrophy, Tesamorelin significantly reduced visceral adipose tissue (VAT) without altering insulin sensitivity, demonstrating its metabolic specificity (NEJM). Preclinical studies also indicate potential benefits for muscle mass maintenance, collagen synthesis, and tissue repair, linked to its ability to raise IGF-1 levels in a controlled manner (PubMed).

Why It’s Studied in Performance & Recovery Research
Because Tesamorelin promotes endogenous GH and IGF-1 signaling, it has drawn research interest in areas related to body composition optimization, recovery, and tissue health. By supporting natural anabolic and repair pathways rather than relying on direct hormone supplementation, it provides a model for studying sustainable growth hormone modulation, metabolic regulation, and tissue resilience (NCBI).